Prevalence of cannabidiol use and correlates in U.S. adults

Drug and Alcohol Dependence Reports, Journal Year: 2024, Volume and Issue: 13, P. 100289 - 100289

Published: Oct. 9, 2024

Cannabidiol (CBD) use has been increasing for its putative therapeutic potential various health conditions. Research using a nationally representative sample is needed to examine characteristics of CBD users. Data came from the adult (N=47,100) 2022 U.S. National Survey on Drug Use and Health. We fitted generalized linear models sociodemographic, health, other substance use, cannabis risk perception as correlates CBD-only CBD-cannabis co-use, compared cannabis-only use. In 2022, 20.6 % 23.0 adults reported cannabis, respectively, in preceding 12 months, 63 users also used cannabis. was significantly higher among women (CBD-only vs. use: IRR=1.43, 95 CI=1.31-1.57), but lower Black Hispanic individuals non-Hispanic White IRR=0.71, CI=0.60-0.85 individuals; IRR=0.79, CI=0.65-0.96 individuals). Older ages, SES, chronic medical conditions, mental illness, high were associated with likelihood versus co-users at most terms disorder, problems. The prevalence self-reported those physical problems warrants public warnings about side effects drug interactions. co-use rate calls more research benefits negative co-use.

Language: Английский

---

A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus

Clinical Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 27, 2024

One in six Americans uses cannabidiol‐based or cannabis‐derived products. Cannabidiol is a substrate of CYP3A, but its role as potential CYP3A inhibitor remains unclear. We hypothesized that cannabidiol would inhibit CYP3A‐mediated metabolism tacrolimus. This report an interim analysis open‐label, three‐period, fixed‐sequence, crossover study healthy participants. Participants first received single dose tacrolimus 5 mg orally. After washout, participants later titrated to mg/kg twice daily for 14 days reach steady state, followed by second Tacrolimus concentrations whole blood were measured UHPLC–MS/MS method. Pharmacokinetic parameters calculated noncompartmental analysis. Twelve completed all periods the study. The maximum concentration ( C max ) increased 4.2‐fold P < 0.0001) with (40.2 ± 13.5 ng/mL) compared without (9.85 4.63 ng/mL). area under concentration‐vs.‐time curve (AUC 0‐∞ 3.1‐fold 0.0001). No change half‐life t 1/2 was observed. demonstrates increases exposure. Our data suggest need reduction and frequent therapeutic monitoring transplant patients taking concomitantly. Whether this observed interaction occurred due inhibition CYP3A4 and/or CYP3A5 liver, intestine, both, intestinal drug transporters (e.g., p‐glycoprotein) during first‐pass elimination be elucidated.

Language: Английский

---

Pharmacological and morphological features and socioeconomic aspects of cannabidiol: A literature review

International Journal of Medicine and Medical Research, Journal Year: 2023, Volume and Issue: unknown, P. 47 - 59

Published: April 26, 2023

The relevance of detailed analysis the available scientific research on effects cannabidiol human body is determined by growing popularity non-psychoactive substance in cannabis products as a medicine. aimed to collect and systematise information about positive negative cannabidiol, well possibilities its use An 3375 articles, publications reports was conducted, which 68 were selected that best met terms request. collected data summarised presented structured format. results review indicate remarkable pharmacological potential can be used promising therapeutic agent various medical fields. In studies reviewed, showed anticonvulsant antiepileptic effects, impact drug substitution programmes. However, possibility reactions potentially harmful also noted: it lead development psychological physical dependence; increases risk physiological disorders, including spermatogenesis disruption female microflora; affects behaviour leads developmental abnormalities. are still not understood, distribution absence sufficient legal regulation may pose health safety consumers. Understanding all aspects will ensure proper management relevant legislative framework, facilitate further new drugs based this plant extract

Language: Английский

---

Updated Risk Assessment of Cannabidiol in Foods Based on Benchmark Dose–Response Modeling

Molecules, Journal Year: 2024, Volume and Issue: 29(19), P. 4733 - 4733

Published: Oct. 7, 2024

Cannabidiol (CBD), a non-psychotropic main component of the

Language: Английский

---

Cannabidiol Use Among Older Adults: Associations with Cannabis Use, Physical and Mental Health, and Other Substance Use

Clinical Gerontologist, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 13

Published: Nov. 22, 2024

To examine older adults' cannabidiol (CBD) use and its associations with cannabis physical/mental health other substance problems.

Language: Английский

---

CBD as a cure‐all? The impacts of state‐level legalization of prescription cannabidiol (CBD) on opioid prescriptions

Southern Economic Journal, Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 26, 2023

Abstract We investigate the impacts of state legalization products containing cannabidiol (CBD), a non‐psychoactive alternative to marijuana, on opioid prescribing rates. Research suggests that legalized medical marijuana may reduce prescriptions, though no empirical link between CBD and opioids has been ascertained. Using county‐level rates 2010 2019, as well state‐level morphine milligram equivalent (MME) consumption 8 common opioids, we estimate adoption limited access cannabis product (CBD) laws leads change in supply‐side measures for through legal open dispensaries, find ability purchase legally 6.6% 8.1% fewer prescriptions at pre‐legalization means, which is essential when evaluating legalization; synthetic control model estimates suggest dispensaries by nearly 3.5% 2 years post‐legalization. also mandating be purchased with an ID or patient registry offsets most potential benefits legalization. Our results provide first evidence that: (i) prescription alone does not usage; (ii) regulations limiting purchasing, such laws, negate all demand‐side (iii) access, either via interstate purchasing are vital using pain‐management substances fully combat epidemic.

Language: Английский

---

None

International Journal of Medicine and Medical Research, Journal Year: 2023, Volume and Issue: 9(1)

Published: June 19, 2023

Low cardiac output syndrome is a prevalent complication observed after surgery, related to elevated rates of mortality and morbidity.The study aimed pinpoint independent risk factors for low through the analysis post-cardiac surgery data.This single-centre, two-year retrospective from January 2021 December 2022, including all patients admitted A1 general intensive care unit postoperative management surgery.Variables preoperative, intraoperative, data were collected evaluated with statistical package social sciences, significance level set at p < 0.05.Overall, median age was 44 years (22-80), 60% being female.The prevalence 44% (n = 85).Significant identified: preoperative left ventricular function (ejection fraction <40%), atrial fibrillation, impaired renal function, multiple valve replacement, prolonged extracorporeal circulation, clamping time.Patients who experienced had longer hospital stays higher incidence complications, fibrillation kidney injury, as well rate (7% versus 0%).Identification treatment can improve myocardial recovery decrease mortality.A better understanding its physiopathological mechanisms may help develop potential preventive strategies

Language: Английский

---